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Background: In surveys of children with allergic rhinitis (AR), nasal congestion has been identified as the most
frequently experienced and bothersome symptom. This analysis was conducted to investigate the effect of
mometasone furoate nasal spray (MFNS) on congestion in children with AR.
Methods: Two multicenter, double-blind, placebo-controlled studies randomly assigned children to MFNS 100 μg
or placebo, 1 spray/nostril QD for 4 weeks (Study 1: ages 6–11 years with seasonal AR [SAR] ≥1 year; Study 2: ages
3–11 years with perennial AR [PAR] ≥1 year). Least square (LS) means were obtained from an ANCOVA model with
treatment and study center effects, with baseline score as a covariate. We conducted post hoc evaluation of
changes from baseline in AM/PM PRIOR (average of reflective AM and PM scores) nasal congestion (0=none to
3=severe).
Results: Study 1: MFNS (n=134) reduced congestion significantly more than placebo (n=135) on day 2 (P=.004) and
on 23/29 days (P≤.037). Change from baseline was −0.53 and −0.28 for MFNS and placebo (P<.001) over days 1–15
and −0.64 and −0.38 for MFNS and placebo (P<.001) over days 1–29. Study 2: MFNS (n=185) reduced congestion
significantly more than placebo (n=189) on day 3 (P=.015) and on 22/29 days (P≤.047). Change from baseline was
−0.56 and −0.36 for MFNS and placebo (P<.001) over days 1–15 and −0.64 and −0.45 for MFNS and placebo
(P<.001) over days 1–29. MFNS was well tolerated, with no unusual or unexpected adverse events.
Conclusion: MFNS effectively relieved nasal congestion and was well tolerated in children with SAR or PAR.
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Controlled clinical trialBackground
Allergic rhinitis (AR) is characterized by a range of symp-
toms, including nasal congestion, nasal itch, sneezing, and
rhinorrhea. A large US survey of 8119 households that in-
cluded 1068 children with AR indicated a 13% prevalence
rate of AR [1], suggesting that millions of children in the
US suffer with this condition; worldwide prevalence has
been reported as high as 12% among children aged 6–7
and 22% among children aged 13–14 [2]. Nasal congestion* Correspondence: eomeltzer@aol.com
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reproduction in any medium, provided the orhas been identified as the most frequently experienced
nasal allergy symptom by 52% of parents of pediatric pa-
tients with AR; parents of children with AR also identified
congestion as the most bothersome symptom. Children
with AR are predisposed to comorbidities such as otitis
media, sinusitis, and asthma [1]; potential complications
associated with AR-related nasal congestion in children
may include sleep impairment, cognitive/emotional/be-
havioral disturbances, and attention deficit/hyperactivity
disorder [3,4]. AR-related nasal congestion may also lead
to breathing through the mouth, with a consequent risk of
orthodontic abnormalities [5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ically active intranasal corticosteroid, has proven to be well
tolerated and effective for the reduction and control of
symptoms associated with seasonal and perennial AR
(SAR and PAR); it is approved for use in children aged
≥2 years [6-8]. In particular, MFNS was shown effective,
at reducing the symptom of congestion in two trials of
adult patients with SAR [9], and, based on these trials and
previous pediatric studies, received an FDA indication for
the treatment of this symptom in patients aged ≥2 years
with SAR [8]. This analysis was designed to evaluate the
efficacy of MFNS in the treatment of nasal congestion in
pediatric patients with SAR or PAR.Methods
Two multicenter, double-blind, placebo-controlled studies
evaluated nasal symptom scores, including congestion, in
children randomly assigned to MFNS 100 μg or placebo, 1
spray per nostril, once daily for 4 weeks. Study 1 (C95-161)
was a phase 2, randomized, parallel-group, active- and
placebo-controlled, double-blind study of children aged 6–
11 years with ≥1 year history of SAR, with a 4-week treat-
ment period. The study was conducted at 20 centers in the
United States. Study 2 (I96-090) was a phase 3, randomized,
parallel-group, placebo-controlled, double-blind, multi-
national study in children aged 3–11 years with PAR, with
a 4-week efficacy and safety period followed by a 6-month
open-label safety period (this open-label period is not
included in the present analysis, as it was not placebo-
controlled and could not be used to draw conclusions
about symptom relief). The study was conducted at 24
medical centers in Argentina, Canada, Chile, Colombia,
Finland, Guatemala, Mexico, Sweden, Uruguay, and
Venezuela. Eligibility criteria for each study are shown in
Table 1. In both studies, blinding of patients and investiga-
tors was maintained using placebo and active treatment
identical in appearance, using a randomization schedule
kept by the sponsor.
Both trials were conducted according to good clinical
practices and the Declaration of Helsinki; an institutional
review board approved the study protocol and statement
of informed consent before initiation at all centers, and all
patients or their guardians provided written informed con-
sent. In Study 1, age-stratified patients were randomly
assigned in a 1:1:1:1:1 ratio to treatment with MFNS 25,
100, or 200 μg once daily; beclomethasone dipropionate
84 μg twice daily; or vehicle placebo, according to a
computer-generated randomization schedule. Only data
from the MFNS 100 μg and placebo groups are presented
in this analysis, as 100 μg is now the approved dose of
MFNS in children. In Study 2, age-stratified patients were
randomly assigned in a 1:1 ratio to treatment with MFNS
100 μg once daily or vehicle placebo, according to acomputer-generated randomization schedule. Study de-
signs are shown in Figure 1.
Study 1 was planned to have a sample size of 500 valid
subjects, or 100 valid subjects per treatment group. This
was estimated to have 90% power to detect a between-
treatment difference of 1.0 points in the primary efficacy
variable using a 2-sided test at an alpha level of 5% with a
pooled standard deviation of 2.27 units. Study 2 was
planned to have a sample size of 150 subjects per treat-
ment group, which was estimated to have 90% power to
detect a between-treatment difference of 0.85 in the pri-
mary efficacy variable using a 2-sided test at an alpha level
of 5% with a pooled standard deviation of 2.27 units.
In both trials, patients and their parents or guardians
rated symptoms including congestion on a scale of 0=no
symptoms to 3=severe symptoms in twice-daily diaries,
indicating their symptom status over the past 12 hours;
physicians assessed symptoms at each visit based on the
patient’s status over the previous 24 hours, up to and in-
cluding the time of the current observations. In Study 1,
the primary efficacy variable was change from baseline
in physician-evaluated total nasal symptom score (TNSS;
sum of rhinorrhea, nasal congestion, nasal itching, and
sneezing) at day 8; in Study 2, the primary efficacy vari-
able was change from baseline in physician-evaluated
TNSS at day 15. For this post hoc analysis, least square
(LS) mean changes from baseline congestion scores were
obtained from an ANCOVA model with treatment and
study center effects, with baseline score as a covariate.
The software used for statistical analysis was SAS ver-
sion 9.2 (SAS Institute, Inc, Cary, NC). Changes from
baseline in congestion are presented according to the
average of AM and PM patient diary entries in each
study, over days 1–15 and 1–29 and for each day.
Safety was assessed by adverse event (AE) monitoring.
Additionally, in Study 1, effects on the hypothalamic-
pituitary-adrenal (HPA) axis were assessed by means of
cosyntropin testing at four designated study centers. Morn-
ing basal plasma cortisol level was determined, followed by
injection of 0.25 mg cosyntropin; after 30 minutes, another
plasma sample was drawn in which subjects were to have
an increase in cortisol level of at least 7 μg/100 mL, with an
absolute value >18 μg/100 mL. Plasma cortisol levels were
analyzed by a 2-way ANOVA that extracted for sources of
variation due to treatment, center, and treatment-by-center
interaction; this analysis included differences between
treatment groups before and after cosyntropin administra-
tion, along with differences between pre- and post-
administration levels and change from screening in differ-
ence between pre- and post-administration levels.
Results
In Study 1, 135 and 136 children with SAR were ran-
domly assigned to MFNS 100 μg and placebo,
Table 1 Eligibility criteria
Study 1 (SAR) Study 2 (PAR)
Inclusion criteria Exclusion criteria Inclusion criteria Exclusion criteria
Aged 6–11 years, of either sex and any
race
Asthma requiring chronic use of inhaled or
systemic corticosteroids
Aged 3–11 years (8–11 years in Chile and Sweden), of
either sex and any race, with ≥1-year history of PAR
requiring over-the-counter or prescription treatment
within the year preceding the study
Asthma requiring chronic use of inhaled or
systemic corticosteroids
≥1-year history of SAR that previously
required treatment
Current or history of frequent, clinically
significant sinusitis or chronic purulent
postnasal drip
Allergic response to ≥1 clinically significant perennial
allergen (house dust mite, perennial indoor mold, or
animal dander prevalent in the subject’s environment)
documented by a positive skin prick test (wheal diameter
≥3 mm larger than diluent control) or intradermal skin test
(wheal diameter ≥7 mm larger than diluent control)
History of or current clinically significant sinus
infection, chronic purulent postnasal drip, rhinitis
medicamentosa, allergies to ≥2 classes of drugs,
allergy to corticosteroids, or posterior subcapsular
cataracts
Positive skin test response to an
appropriate tree and/or grass seasonal
allergen within the last year
Rhinitis medicamentosa Nasal congestion score ≥2 (indicating a symptom of at
least moderate intensity), TNSS ≥5 at both screening and
baseline visits
Nasal structural abnormalities, including large
nasal polyps or marked septal deviation, that
significantly interfere with nasal airflow
Clinically symptomatic at both
screening and baseline; nasal
congestion at least moderate (score ≥2)
with a total nasal symptom score ≥6
Upper respiratory tract or sinus infection
that required antibiotic therapy within the
previous 2 weeks, or a viral upper respiratory
infection within 7 days prior to screening
Investigator-assessed overall PAR score ≥2 at baseline,
and at least moderate rhinorrhea and/or congestion
documented in a subject treatment diary for ≥4 of
the 7 days prior to baseline
Treatment with inhaled corticosteroids for
asthma for ≥2 months within the 12 months
prior to enrollment or within 1 month before
enrollment or 2 courses of systemic steroids,
or any course lasting ≥14 days, within the 12
months preceding enrollment
Receiving immunotherapy (desensitization
therapy), unless on a stable maintenance
schedule for at least 1 month prior
to screening
Free of any clinically significant disease, other
than AR, that could interfere with study evaluations




















Figure 1 Study designs. BDP, beclomethasone dipropionate; MFNS, mometasone furoate nasal spray; PAR, perennial allergic rhinitis; SAR,
seasonal allergic rhinitis. Gray lines indicate study arms or phases not included in this analysis of congestion results.
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were randomly assigned to MFNS 100 μg and placebo.
Baseline characteristics are shown in Table 2. Efficacy
data were available for 134 and 135 patients with SAR
assigned to MFNS 100 μg and placebo, respectively,
from Study 1; efficacy data were available for 185 and
189 patients assigned to MFNS 100 μg and placebo, re-
spectively, from Study 2. Mean baseline nasal congestion
score was >2 in all treatment groups, indicating that the
children studied had moderate to severe obstruction.Table 2 Baseline characteristics
Study 1 (SAR)
MFNS 100 μg (n=135) P
Age (years)
Mean (95% CI) 8.7 (8.5, 9.0) 8
Sex (%)
Male 84 (62) 8
Race (%)
White 111 (82) 1
Nonwhite 24 (18) 2
Asthma history,
n (%) 46 (34) 6
Congestion score, LS mean (95% CI)a 2.20 (2.10, 2.31) 2
PAR, n (%) 95 (70) 9
SAR, n (%) 135 (100) 1
aScale of 0=no congestion to 3=severe congestion.
CI=, confidence interval; LS=, least squares; MFNS, mometasone furoate nasal sprayEfficacy
In both studies, MFNS was associated with significantly
greater relief of congestion vs. placebo over the first half
of the study and over the entire treatment period.
Change from baseline over days 1–15 and 1–29 in both
studies is shown in Figure 2. In the SAR study, conges-
tion was reduced by 0.53 points (23.7%) and 0.28 points
(7.8%) over days 1–15 for MFNS and placebo, respect-
ively (P<.001) for a treatment difference of 0.25 points
(95% confidence interval [CI], 0.12 to 0.38); over days 1–Study 2 (PAR)
lacebo (n=136) MFNS 100 μg (n=190) Placebo (n=191)
.8 (8.6, 9.1) 7.6 (7.3, 8.0) 7.4 (7.1, 7.8)
4 (62) 123 (65) 109 (57)
13 (83) 86 (45) 89 (47)
3 (17) 104 (55) 102 (53)
2 (46) 62 (33) 62 (33)
.11 (2.00, 2.22) 2.02 (1.94, 2.10) 2.07 (1.99, 2.15)
0 (66) 190 (100) 191 (100)
36 (100) 52 (27) 42 (22)
; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.
Figure 2 Change from baseline congestion score over days 1–15 and 1–29. *P<.05 vs. placebo. MFNS, mometasone furoate nasal spray;
PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.
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0.38 points (12.1%) for placebo (P<.001), for a treatment
difference of 0.26 points (95% CI, 0.12 to 0.40). In the
PAR study, congestion was reduced by 0.56 points
(22.7%) and 0.36 points (16.6%) over days 1–15 for
MFNS and placebo (P<.001), for a treatment difference
of 0.20 points (95% CI, 0.09 to 0.31); over days 1–29, re-
ductions were 0.64 (28.2%) for MFNS vs. 0.45 (21.7%)
for placebo (P<.001), for a treatment difference of 0.19
points (95% CI, 0.07 to 0.30). In both studies, the magni-
tude of treatment effect seen between days 1–15 and
days 1–29 was comparable, indicating a lack of tolerance
over the treatment period.
In Study 1, MFNS 100 μg was associated with signifi-
cantly greater reduction of congestion vs. placebo inFigure 3 Daily change from baseline in AM/PM congestion score, Stu
15, 18, 22, and 23. MFNS, mometasone furoate nasal spray; SAR, seasonal achildren with SAR, first observed on day 2 (P=.004) and
on 23 of the 29 total days (P≤.037). Daily change from
baseline congestion score in Study 1 is shown in Figure 3.
Daily percentage reduction from baseline ranged from
1.9% on day 1 to 41.7% on day 26 for MFNS and from an
increase of 1.0% on day 1 to 21.2% on day 23 for placebo.
Daily treatment effect ranged from 0.03 to 0.41 points.
In Study 2, MFNS 100 μg was also associated with sig-
nificantly greater congestion reduction vs. placebo in chil-
dren with PAR, with significance first seen at day 3
(P=.015) and on 22 of the 29 total days (P≤.047). Daily
change from baseline congestion score in Study 2 is shown
in Figure 4. Daily percentage change from baseline ranged
from an increase of 2.8% on day 1 to a reduction of 40.3%
on day 29 for MFNS and reductions from 0.2% on day 1dy 1 (SAR). Treatment difference P<.05 on all days except days 1, 10,
llergic rhinitis.
Figure 4 Daily change from baseline in AM/PM congestion score, Study 2 (PAR). Treatment difference P<.05 on all days except days 1, 2, 7,
17, 18, 20, and 29. MFNS, mometasone furoate nasal spray; PAR, perennial allergic rhinitis.
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ranged from 0.09 to 0.25 points.
As reported elsewhere, both trials met their primary
end points (change from baseline in physician-evaluated
TNSS at day 8 in Study 1 and at day 15 in Study 2) [6,7].
Safety
Adverse events (AEs) were similar between treatment
groups in both studies; in Study 1, treatment-emergent
AEs were reported in 67% and 62% of patients receiving
MFNS 100 μg and placebo, respectively, and in Study 2,
treatment-emergent AEs were reported in 57% and 58%
of patients receiving MFNS and placebo. Most AEs were
mild or moderate in severity, and most AEs were consid-
ered by the investigator to be unrelated to treatment.
Table 3 shows all AEs, all treatment-related AEs, and se-
vere treatment-related AEs.
In the assessment of HPA axis effects conducted in
Study 1, mean plasma cortisol levels before and after
cosyntropin stimulation were similar between MFNS and
placebo groups after 4 weeks of treatment (prestimulation,
10.15 [SD, 3.90] and 10.13 [SD, 3.14] μg/100 mL;
poststimulation, 26.47 [SD, 3.71] and 25.95 [SD, 3.67] μg/
100 mL for MFNS 100 μg and placebo, respectively).
Plasma cortisol level ranges did not suggest an outlier
effect.
Discussion
In this analysis, MFNS 100 μg once daily was shown to be
effective in the treatment of nasal congestion in children,
whether caused by seasonal or perennial AR. Treatment
effect was comparable between the study of patients with
SAR and the study of patients with PAR. Though these
studies were primarily designed to evaluate total nasal
symptom score and not congestion score in particular, the
between-treatment difference in congestion score overdays 1–15 was −0.25 in the SAR study and −0.20 in the
PAR study; this was comparable to the effect size of −0.23
over days 1–15 in pooled results of adult studies designed
to evaluate the effect of MFNS for nasal congestion associ-
ated with SAR [9]. Results of the adult studies of the effect
of MFNS on nasal congestion in SAR led to its becoming
the first, and thus far the only, intranasal corticosteroid
(INS) to receive FDA approval for the treatment of this
symptom in patients with SAR [8].
Rather than focusing on congestion, most previous eval-
uations of MFNS in pediatric populations have used the
total nasal symptom score as the primary efficacy variable.
However, one much smaller study (N=20) evaluated the
effects of MFNS on nasal congestion in children and ado-
lescents with PAR as measured by symptom score and the
objective measurement of acoustic rhinometry [10]. Mean
nasal obstruction score was reduced by 50% after 21 days
of treatment with MFNS 100 μg daily, and acoustic
rhinometry showed significant increases in nasal volume
after treatment. This small study was limited by a lack of
placebo control; the present analysis found that the reduc-
tion from baseline congestion seen with mometasone was
superior to that seen with vehicle placebo.
The lack of an adverse effect on the HPA axis, and over-
all positive safety profile, seen with MFNS in these efficacy
studies correspond to the findings of prospective evalua-
tions of the safety of MFNS in pediatric populations
[11,12]. Administration of MFNS 100 μg for 1 year was
found to have no effect on growth or HPA axis function
per cosyntropin stimulation testing in a study of 98 chil-
dren with PAR [11]. Assessment of short-term effects also
found no effect of MFNS on plasma cortisol levels in chil-
dren aged 6–12 years, even at a dosage of 200 μg daily for
7 days [12]. In both these studies, AE rates were similar
between MFNS and placebo, as was also seen in the 2
studies examined here [11,12]. Together with the efficacy
Table 3 Adverse events
Study 1 (SAR) Study 2 (PAR)








AEs reported by ≥5% of
patients
Any, 91 (67) Any, 93 (67) Any, 108 (57) Any, 110 (58)
Fever, 9 (7) Fever, 11 (8) Coughing, 27 (14) Coughing, 33 (17)
Headache, 30 (22) Headache, 26 (19) Headache, 24 (13) Headache, 25 (13)
Vomiting, 7 (5) Asthma, 12 (9) Fever, 16 (8) Fever, 15 (8)
Asthma, 8 (6) Coughing, 11 (8) Pharyngitis, 14 (7) Pharyngitis, 14 (7)
Coughing, 7 (5) Epistaxis, 10 (7) Epistaxis, 12 (6) Epistaxis, 17 (9)
Epistaxis, 12 (9) Pharyngitis, 15 (11) Viral infection, 14 (7)
Pharyngitis, 9 (7) Sneezing, 7 (5)
Treatment-related AEs, n (%) Any, 27 (20) Any, 31 (23) Any, 28 (15) Any, 31 (16)
Chest pain, 1 (1) Edema, 1 (1) Erythema, 1 (1) Fatigue, 1 (1)
Fatigue, 1 (1) Headache, 8 (6) Fever, 1 (1) Fever, 2 (1)
Headache, 4 (3) Nausea, 1 (1) Headache, 6 (3) Headache, 5 (3)
Diarrhea, 1 (1) Insomnia, 1 (1) Malaise, 1 (1) Crying, abnormal,
1 (1)
Dyspepsia, 1 (1) Somnolence, 1 (1) Dyspepsia, 1 (1) Dizziness, 1 (1)
Nausea, 1 (1) Coughing, 1 (1) Nausea, 1 (1) Hypokinesia, 1 (1)
Vomiting, 1 (1) Epistaxis, 9 (7) Vomiting, 2 (1) Diarrhea, 1 (1)
Asthma aggravated, 2 Nasal burning, 2 (1) Earache, 1 (1) Dyspepsia, 2 (1)
(1) Pharyngitis, 3 (2) Leukorrhea, 1 (1) Nausea, 1 (1)
Bronchitis, 1 (1) Rhinitis, 2 (1) Otitis media, 1 (1) Vomiting, 1 (1)
Coughing, 2 (1) Sneezing, 6 (4) Coughing, 3 (2) Appetite increased,
1 (1)
Dyspnea, 1 (1) Upper respiratory tract infection, 1 (1) Epistaxis, 7 (4) Infection bacterial,
1 (1)
Epistaxis, 8 (6) Nasal burning, 1 (1) Coughing, 5 (3)
Nasal irritation, 3 (2) Nasal irritation, 1 (1) Epistaxis, 9 (5)
Pharyngitis, 1 (1) Pharyngitis, 2 (1) Nasal congestion, 1
(1)
Rhinitis, 1 (1) Rhinorrhea, 1 (1) Nasal irritation, 1 (1)
Sneezing, 4 (3) Sneezing, 5 (3) Pharyngitis, 1 (1)
Eczema, 1 (1) Rhinitis, 1 (1)
Rash, 2 (1) Rhinorrhea, 1 (1)







1 (1) (headache) 4 (3) (epistaxis, rhinitis, sneezing,
conjunctivitis)
1 (1) (dyspepsia) 1 (1) (nasal
congestion)
AEs, adverse events; MFNS, mometasone furoate nasal spray; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.
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MFNS 100 μg suggests its suitability for long-term therapy
in pediatric patients with AR.
This analysis indicates that baseline congestion was
similar between Study 1 and Study 2. Thus, the populationdid not correspond to a pattern observed in other research
showing PAR to be more strongly associated with nasal
congestion than SAR [13,14]. However, there was consid-
erable overlap between types of rhinitis; overall, roughly 3/
5 of patients in the SAR study also had PAR, and 1/4 of
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search has found similar overlap between types in a stud-
ied population [15]. The authors of the Allergic Rhinitis
and its Impact on Asthma (ARIA) guidelines identify the
seasonal/perennial classifications based on allergen trig-
gers as inadequate and, rather, classify AR as “intermit-
tent” (present <4 days a week or <4 weeks) or “persistent”
(present >4 days a week and >4 weeks), although they note
in their most recent guideline update that little research
thus far has employed these classifications [16,17]. Despite
the fact that MFNS was consistently effective in the
present analysis regardless of whether AR was perennial
or seasonal, it cannot be determined whether categorizing
the subjects according to ARIA standards, or considering
those patients who only had SAR or PAR and not the
other as well, would have had any effect on the observed
efficacy.
The impact and burden of AR in children (and their
caregivers) has been well documented. In a survey of
children and adolescents using the Child Health Question-
naire (CHQ-PF50), respondents with AR reported signifi-
cantly worse results not just in general health and physical
functioning but also in compromises in emotional status,
mental health, self-esteem, and a number of other areas
[18]. Relatively little research has been directed specifically
at the symptom of nasal congestion and its impact and
treatment in pediatric populations with AR. However,
nasal congestion is known to be prevalent and bothersome
in this population; in a survey including 500 children diag-
nosed with AR, nasal congestion was identified as the
most frequently experienced nasal allergy symptom and
was said to occur either every day (25%) or most days
(27%) each week during their worst month for allergy
symptoms [1]. Parents of children with AR also most
frequently (27%) identified congestion as the most bother-
some symptom [1]. A survey of 2355 individuals included
460 who were primary caregivers of children suffering
from AR; of these, 63% identified congestion as the
symptom their children most wanted to prevent and the
symptom most likely cause to trigger a visit to a physician
(69%) [19].
As can adults, children with AR and nasal congestion
can suffer sleep disturbances, with the associated prob-
lems stemming from lack of quality sleep. A survey in-
cluding 6349 children aged 5–14 years found that AR
symptoms were experienced in the past year by 63.2% of
habitual snorers vs 33.9% of nonsnorers (P<.001) [20].
Habitual snorers, in turn, were found to include a
greater proportion of subjects with poor temper, hyper-
activity, and poor school performance vs. nonsnorers.
Children with AR-related nasal congestion can suffer
sleep disturbances, including not just snoring but also
restless sleep and difficulty awakening, with associated
daytime sleepiness and irritability [3]. Effective treatmentof congestion, including INS therapy, can provide better
quality of sleep and result in better quality of life during
the day. A small study (N=14) of children aged 4–9 years,
all of whom had PAR with seasonal exacerbations and
sleep problems such as snoring, being difficult to wake,
or daytime somnolence, treated subjects with 64 μg in-
tranasal budesonide per nostril QD for approximately
6 weeks. After treatment, subjects showed significantly
improved sleep quality, as measured by change in apnea-
hypopnea index (from 7.6 to 0.9, P=.004) and respiratory
disturbance index (from 8.4 to 1.2; P=.005). These im-
provements were also reflected in quality-of-life scores
related to sleep disturbance and its consequences [3].
The source data of the present analysis did not include
evaluations of quality of life or sleep quality; thus, a limi-
tation of these post hoc findings regarding the effects of
MFNS on nasal congestion is that they cannot be
assessed for relevance to quality of life or sleep.
The challenges of treating congestion in the pediatric
population are complicated by the fact that children may
not be able to articulate their symptoms to caregivers or
physicians, potentially leading to missed diagnoses and
undertreatment. Further, congestion related to AR pre-
sents several unique burdens in the pediatric population.
Children with nasal congestion are likely to breathe
through the mouth [21]. A study of 370 children aged
3–9 years, 204 of whom were chronic mouth-breathers,
found that 81.4% had allergic rhinitis; children who
breathed through the mouth had 78.4 times the odds of
suffering nasal congestion daily [21]. Chronic mouth
breathing in children is of concern, as it has the poten-
tial to affect craniofacial development [22,23]. Such pos-
sible complications, along with the fact that pediatric AR
has been associated with asthma, adenoidal hypertrophy,
attention deficit hyperactivity disorder, otitis media with
effusion, and a 10-fold increased risk of sinus disease
[1,24-27], underscore the potential adverse consequences
of AR. Again, the source data of the present analysis did
not incorporate evaluation of these potential comorbidities
or complications and cannot be used to assess proper
therapeutic management of them. Additional studies are
needed on the impact of nasal congestion in children, the
importance of its proper treatment, and the relationship of
treatment options to complications of congestion.
Conclusions
In this post hoc analysis, MFNS 100 μg/day demonstrated
significant efficacy vs. nasal congestion in pediatric pa-
tients with both SAR and PAR, as seen in daily scores and
over the course of treatment, as early as day 2 in Study 1
and day 3 in Study 2. MFNS was well tolerated in both
SAR and PAR studies. These results indicate that MFNS
may be a safe and effective treatment choice for children
with congestion caused by seasonal and perennial AR.
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